CONGRESSO NAZIONALE IMI BOLOGNA, 10-12 NOVEMBRE 2019 ROYAL HOTEL CARLTON Via Montebello, 8
Total Page:16
File Type:pdf, Size:1020Kb
CONGRESSO NAZIONALE IMI BOLOGNA, 10-12 NOVEMBRE 2019 ROYAL HOTEL CARLTON Via Montebello, 8 rgrupp rgrupp te o te o in in m m e o o e l l n n a a a a n n i i l l o o a a m m t t i i a a ABSTRACT BOOK ABSTRACT Sommario ABSTRACT AREA EPIDEMIOLOGIA GENETICA E PATOGENESI .............................................................................................................................................................................. 4 Two pathways of nevus associated melanoma: clinical and dermoscopic characteristics ..................................................................................................................................... 4 Vitamin D and disease free survival in stage II melanoma ..................................................................................................................................................................................... 5 Progetto IMI Tele-consulenza genetica (TG): utilizzo di strumenti di telemedicina per consulenza genetica e test molecolare di predisposizione al melanoma. Risultati preliminari. ............................................................................................................................................................................................................................................................. 7 Mutation screening at germline and somatic levels in patients with multiple primary melanomas ..................................................................................................................... 8 Caratterizzazione genomica del melanoma acrale ................................................................................................................................................................................................. 9 Proposta di management per pazienti affetti da Melanoma Familiare e Multiplo .............................................................................................................................................. 11 The association between pesticide use and cutaneous melanoma: a systematic review and meta-analysis. ..................................................................................................... 12 Progetto per la ricerca dei determinanti genetici alla base dello sviluppo e della risposta al trattamento. ........................................................................................................ 14 ABSTRACT AREA PREVENZIONE E DIAGNOSI ...................................................................................................................................................................................................... 15 CT and FDG PET/CT imaging in Melanoma Patients: rationale, strengths and weaknesses, radiation exposure and relative risks .................................................................... 15 A case of a pigmented epithelioid melanocytoma of mucosal site ...................................................................................................................................................................... 16 Reazioni avverse cutanee indotte dai nuovi farmaci antitumorali ....................................................................................................................................................................... 18 Multidisciplinary management of patients with malignant melanoma: the experience of the Melanoma Unit of Sassari (MUS). ..................................................................... 19 Melanoma indotto da farmaci oncologici? ........................................................................................................................................................................................................... 20 L’ecografia dei tessuti molli nel melanoma .......................................................................................................................................................................................................... 21 La Prevenzione “Social” nella lotta al melanoma: nuove strategie di informazione e comunicazione su Facebook ........................................................................................... 22 Rapid On-Site Evaluation (ROSE) without EBUS in the diagnosis of polypoid melanoma metastasis: a case report ........................................................................................... 23 LIGHT BROWN STRUCTURELESS AREAS AS PREDICTOR OF MELANOMA IN SITU ................................................................................................................................................ 29 AREA CLASSIFICAZIONE PATOLOGICA E MOLECOLARE....................................................................................................................................................................................... 30 MELANOMA MALIGNO SARCOMATOIDE VS SARCOMA A CELLULE CHIARE: CASE REPORT ................................................................................................................................ 30 Prognostic utility of CAF1 (p60 and p150 subunits) expression in uveal melanoma. ........................................................................................................................................... 32 P16 EXPRESSION IN UVEAL MELANOMA metastases: A DIGITAL APPROACH. ..................................................................................................................................................... 33 Intra-patient heterogeneity of BRAF, NRAS, and c-KIT molecular alterations during melanoma progression .................................................................................................... 34 AREA CHIRURGIA ............................................................................................................................................................................................................................................... 35 1 Multiple lymphatic-venous anastomoses in reducing the risk of lymphedema in melanoma patients undergoing complete lymph node dissection. ..................................... 35 Mancata visualizzazione di linfonodi sentinella alla linfoscintigrafia preoperatoria nel melanoma: studio retrospettivo della casistica della Chirurgia Plastica ISG dal 2004 al 2018. ..................................................................................................................................................................................................................................................................... 36 Approccio C.O.R.E. nel trattamento dei tumori cutanei del distretto cervico-facciale ........................................................................................................................................ 37 METASTASI DI MELANOMA IN SEDE ATRIALE : CASE REPORT .............................................................................................................................................................................. 38 RUOLO DELLA LINFOADENECTOMIA RADICALE E SUE COMPLICANZE NEI MELANOMI AL TERZO STADIO .......................................................................................................... 39 8ª edizione AJCC: quale impatto in termini clinico-assistenziali? Analisi della nostra casistica di melanomi sottili. ........................................................................................... 40 AREA TERAPIA MEDICA ..................................................................................................................................................................................................................................... 41 Linfonodo sentinella nel melanoma spesso (Breslow > 4mm): la nostra esperienza chirurgica .......................................................................................................................... 41 Role of 18F- fluorodeoxyglucose positron emission tomography/computed tomography (18FDG- PET/CT) baseline metabolic parameters as prognostic factors in melanoma patients treated with immunotherapy: a retrospective analysis. ...................................................................................................................................................... 42 Attività sinergica degli inibitori di ATR e di PARP in linee cellulari di melanoma con mutazione di BRAF ........................................................................................................... 44 Concomitant medications during immunotherapy may influence immune related adverse events (irAEs) onset .............................................................................................. 45 A RETROSPECTIVE REAL-WORLD STUDY OF CUTANEOUS TOXICITY OF IMMUNE CHECKPOINTS INHIBITORS IN PATIENTS WITH ADVANCED MELANOMA ............................. 46 Combined inhibition of MEK and Notch blocks migration and triggers senescence in GNAQQ209L mutated uveal melanoma cells .................................................................... 47 SURVEY IMI: Experience about management of immunotherapy toxicities ........................................................................................................................................................ 48 Sustained complete response to Nivolumab in two cases of GNAQ mutant uveal melanoma with non-hepatic metastatic disease................................................................. 49 ErbB3 phosphorylation as central event in adaptive resistance to BRAF/MEK inhibitors in metastatic